EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression

Nicola E Annels, M Denyer, D Nicol, S Hazell, A Silvanto, M Crockett, M Hussain, Carla Moller-Levet, Hardev Pandha

Cancer Immunology, Immunotherapy · 2023-12 · 72 (12) · 4221-4234

DOI: 10.1007/s00262-023-03558-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 08.11.2023. Verfasst von Nicola E Annels und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Topic of Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma is an immunogenic tumour with a prominent dysfunctional immune cell infiltrate, unable to control tumour growth. Although tyrosine kinase inhibitors and immunotherapy have improved the outlook for some patients, many individuals are non-responders or relapse despite treatment. The hostile metabolic environment in RCC affects the ability of T-cells to maintain their own metabolic programme constraining T-cell immunity in RCC. We investigated the phenotype, function and metabolic capability of RCC TILs correlating this with clinicopathological features of the tumour and metabolic environment at the different disease stages. Flow cytometric analysis of freshly isolated TILs showed the emergence of exhausted T-cells in advanced disease based on their PD-1 high and CD39 expression and reduced production of inflammatory cytokines upon in vitro stimulation. Exhausted T-cells from advanced stage disease also displayed an overall phenotype of metabolic insufficiency, characterized by mitochondrial alterations and defects in glucose uptake. Nanostring nCounter cancer metabolism assay on RNA obtained from 30 ccRCC cases revealed significant over-expression of metabolic genes even at early stage disease (pT1-2), while at pT3-4 and the locally advanced thrombi stages, there was an overall decrease in differentially expressed metabolic genes. Notably, the gene PPARGC1A was the most significantly down-regulated gene from pT1-2 to pT3-4 RCC which correlated with loss of mitochondrial function in tumour-infiltrating T-cells evident at this tumour stage. Down-regulation of PPARGC1A into stage pT3-4 may be the ‘tipping-point’ in RCC disease progression, modulating immune activity in ccRCC and potentially reducing the efficacy of immunotherapies in RCC and poorer patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansNeoplasm Recurrence, LocalDisease ProgressionImmunity

Stichwörter der Autor:innen

Renal Cell carcinomaT-cell exhaustion metabolic

Autor:innen und Institutionen

  • Oncology, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
  • Royal Marsden Hospital, Fulham Road, London, UK.
  • Frimley Park Hospital, Frimley, Camberley, UK.
  • Bioinformatics Core Facility, University of Surrey, Guildford, UK.
  • Oncology, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK. h.pandha@surrey.ac.uk.

Förderung

  • Topic of Cancer

Zitieren

APA

Annels, N. E., Denyer, M., Nicol, D., Hazell, S., Silvanto, A., Crockett, M., Hussain, M., Moller-Levet, C., & Pandha, H. (2023). The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression. Cancer Immunology, Immunotherapy, 72(12), 4221-4234. https://doi.org/10.1007/s00262-023-03558-5

Vancouver

Annels NE, Denyer M, Nicol D, Hazell S, Silvanto A, Crockett M, et al. The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression. Cancer Immunology, Immunotherapy. 2023;72(12):4221-4234. doi:10.1007/s00262-023-03558-5

BibTeX
@article{Annels2023,
  author = {Annels, Nicola E and Denyer, M and Nicol, D and Hazell, S and Silvanto, A and Crockett, M and Hussain, M and Moller-Levet, Carla and Pandha, Hardev},
  title = {The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {12},
  pages = {4221--4234},
  doi = {10.1007/s00262-023-03558-5}
}
Kostenlos starten →